Pfizer’s COVID-19 Franchise Dominates Best-Seller List

Paxlovid Rose As Cominarty Slowed And Humira Came In Third

Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.

Drugs and Money
• Source: Shutterstock

Through the first three quarters of 2022, sales of the biopharmaceutical industry’s top products were largely at a steady state except for COVID-19 products, where the antiviral for infected patients became the top seller in the third quarter while vaccines that held the top two spots during each of the first two quarters declined sharply.

Not among the 10 highest-selling drugs during the first quarter of 2022, Pfizer Inc.’s Paxlovid (nirmatrelvir/ritonavir) rose to second...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Scrip Perspectives

More from Scrip